Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
Eur J Immunol. 1995 Nov;25(11):3079-86. Unique Identifier : AIDSLINE MED/96085179 Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z; Lauritzsen GF; Institute of Immunology and Rheumatology, University of Oslo,; Norway.
Abstract:
CD4+ T cells can recognize a processed idiotypic peptide derived from the mouse lambda 2(315) immunoglobulin light chain. The idiotypic peptide is presented on the I-E(d) class II major histocompatibility complex molecule. Mice made transgenic for a lambda 2(315)-specific alpha beta T cell receptor have been demonstrated to be specifically resistant against a tumor challenge with the MOPC315 (alpha,lambda 2(315)) plasmacytoma (Lauritzsen, G. F., Weiss, S., Dembic, Z. and Bogen, B., Proc. Natl. Acad. Sci. USA 1994, 91: 5700). That study, however, did not rule out a role of either anti-Id antibodies or T cells expressing nontransgenic specificities due to expression of endogenous T cell receptor (TcR) alpha chains. Also, the role of different T cell subsets in protection was unclear. To remove these ambiguities, we have now made the transgenic mice homozygous for the scid mutation, known to inhibit both Ig and TcR gene rearrangements. Such transgenic SCID mice lack B cells and antibodies while they still have plenty of CD4+ and CD4-8- cells expressing the transgenic alpha beta T cell receptor. The number of CD8+ T cell is dramatically reduced. Even so, transgenic SCID mice are protected against a challenge with MOPC315 plasmacytoma cells. Therefore, B cells, as well as novel T cell receptor specificities created by rearrangements of endogenous alpha-chain genes, are both dispensable for effective immunosurveillance in our system. Surprisingly, we found that transgenic CD8+ and CD4-8- cells are idiotype-specific and I-E(d) restricted. However, these T cell subsets are not required for resistance because adoptive transfer experiments demonstrated that highly purified transgenic SCID CD4+ cells suffice for tumor protection.
Keywords: Animal Antibodies, Anti-Idiotypic/*IMMUNOLOGY CD4-Positive T-Lymphocytes/*IMMUNOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY Female Gene Rearrangement, B-Lymphocyte/GENETICS Gene Rearrangement, T-Lymphocyte/GENETICS Immunoglobulins/BLOOD/GENETICS Immunotherapy, Adoptive/METHODS Lymphoid Tissue/IMMUNOLOGY Male Mice Mice, Inbred BALB C Mice, SCID Mice, Transgenic Neoplasm Transplantation/*IMMUNOLOGY Neoplasms, Experimental/*IMMUNOLOGY/PREVENTION & CONTROL Receptors, Antigen, T-Cell/GENETICS Support, Non-U.S. Gov't JOURNAL ARTICLE 960330
M9630715
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
